Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

294.00 -0.53 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
47 48 Next >
Is Amgen The Rare Biotech With A Safe Dividend?
Amgen pays a $2.25 per share quarterly dividend, which comes out to a 3.3% yield. Biotech can be notoriously volatile, though, so can investors count on receiving the same dividend quarter after... 
Via Talk Markets
7 Analysts Have This To Say About Amgen
Via Benzinga
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Amgen Unusual Options Activity For April 02
Via Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is Amgen Stock a Buy Now?
There are some worrying signs. 
Via The Motley Fool
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Redditors Identify 'Best Undervalued Stocks' For 2024
Savvy investors at Reddit discuss undervalued stocks for potential growth. Top picks include META, Google, Starbucks, Verizon, and others, with varied perspectives on their potential. 
Via Benzinga
Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says
Raymond James resumes coverage of Amgen highlighting its diversified portfolio and strong presence across therapeutic areas for sustainable long-term growth. Innovative pipeline in oncology, rare... 
Via Benzinga
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
7 Dow Stocks to Buy on the Dip: March 2024
Analysts expect that the market may be heading toward a correction. These are seven of the best Dow stocks to buy when prices pull back. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
Buffett’s Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating
Warren Buffett stocks and Berkshire Hathaway's portfolio of companies are hidden investment vehicles hiding in plain sight. 
Via InvestorPlace
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now. 
Via InvestorPlace
Hot Stocks: The 3 Best Opportunities for Investing in the Dow
Although these Dow stocks are mature enterprises, they still have enough in the tank to pull off some surprises. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
4 Oversold Large Cap Stocks Yielding High Dividends
Overlooked, oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns
The Dogs of the Dow strategy is one of the best yearly strategies investors should use to make some good money. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
With therapeutics focused on slimming down skyrocketing, it’s time to consider these top weight-loss stocks. 
Via InvestorPlace
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?
It's only a bargain price if it's actually worth owning. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
It’s Time! 3 Dodgy Pharma Stocks to Sell in February
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action. 
Via InvestorPlace
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
The biotech tantalized investors with a very promising data update. 
Via The Motley Fool
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.